Clinical Trial

Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

Unknown Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated September 13, 2023 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The Purpose of This Study is to Evaluate the Efficacy and Safety of Gemox combined with Anlotinib and Sintilimab as first-lineTherapy for Patients With advanced combined hepatocellular-cholangiocarcinoma.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06033118
Lead Sponsor Sichuan University
Conditions Combined Hepatocellular Cholangiocarcinoma
Enrollment 25 participants
Start Date 2023-10-01
Primary Completion 2025-07-31 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2023-09-13